Last reviewed · How we verify
Prof-001
At a glance
| Generic name | Prof-001 |
|---|---|
| Sponsor | ProFem GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC) (PHASE2, PHASE3)
- ProF-001_Phase IIa (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prof-001 CI brief — competitive landscape report
- Prof-001 updates RSS · CI watch RSS
- ProFem GmbH portfolio CI